Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Betaprodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.67 |
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.56 |
| ▸ | OPRD1 known ✓ | P41143 | 5/20 | 0.56 |
| ▸ | OPRK1 known ✓ | P41145 | 4/20 | 0.56 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.50 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.45 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alphaprodine SCHEMBL8818643 | 1.00 | LMNA (1.00) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Betaprodine SCHEMBL186644 | 0.99 | LMNA (0.97) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Betaprodine SCHEMBL248367 | 0.99 | LMNA (0.97) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Alphaprodine SCHEMBL25054 | 0.99 | LMNA (0.97) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Betaprodine SCHEMBL25053 | 0.99 | LMNA (0.97) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Betaprodine SCHEMBL1649307 | 0.96 | LMNA (0.93) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Proheptazine SCHEMBL25539 | 0.91 | LMNA (0.84) | LMNADRD3NPSR1OPRM1OPRD1 | |
| SCHEMBL11383571 | 0.88 | LMNA (0.78) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Betaprodine SCHEMBL4283575 | 0.87 | LMNA (0.77) | LMNADRD3NPSR1OPRM1OPRD1 | |
| SCHEMBL8977860 | 0.87 | LMNA (0.77) | LMNADRD3NPSR1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0906104-A4 | METHOD FOR TREATING PAIN | LILLY CO ELI (US) | 2003-12-10 | — | — | EP | claimed |
| US-20030013689-A1 | Method for treating pain | HELTON DAVID REED (US) | 2003-01-16 | — | — | US | claimed |
| US-6444665-B1 | USING AN ATYPICAL ANTIPSYCHOTIC COMPOUND TO PROVIDE ANALGESIC ACTIVITY; RISPERIDONE, CLOZAPINE, SEROQUEL, SERTINDOLE, ZIPRASIDONE, AND ZOTEPINE | ELI LILLY AND COMPANY | 2002-09-03 | — | — | US | claimed |
| JP-2000507544-A | — | — | 2000-06-20 | — | — | JP | claimed |
| EP-0906104-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-04-07 | — | — | EP | claimed |
| WO-1997035584-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-10-02 | — | — | WO | claimed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200390780-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2020-12-17 | — | — | US | disclosed |
| US-10660899-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-05-26 | — | — | US | disclosed |
| EP-2272508-B1 | Pharmaceutical formulations for dry powder inhalers | VECTURA LTD (GB) | 2020-03-25 | — | — | EP | disclosed |
| US-10561613-B2 | Method of making particles for use in a pharmaceutical composition | VECTURA LIMITED (GB) | 2020-02-18 | — | — | US | disclosed |
| EP-2266549-B1 | METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION | VECTURA LTD (GB) | 2019-08-07 | — | — | EP | disclosed |
| EP-1296651-B2 | METHOD OF MAKING PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION | VECTURA LTD (GB) | 2019-07-17 | — | — | EP | disclosed |
| EP-0906104-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5891842-A | CONCURRENT ADMINISTRATION OF AN OPIOD AND SUBSTANCE P OR PRECURSORS | TRUSTEES OF TUFTS COLLEGE (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1997035584-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-10-02 | — | — | WO | disclosed |
| US-4334526-A | Method for administering a dissociative, unconscious type of anesthesia | HAMACHER EDWARD N | 1982-06-15 | — | — | US | disclosed |
| US-4334526-A | Method for administering a dissociative, unconscious type of anesthesia | HAMACHER EDWARD N | 1982-06-15 | — | — | US | disclosed |
| US-4246894-A | Method and system for administering a dissociative, unconscious type of anesthesia | HAMACHER EDWARD N | 1981-01-27 | — | — | US | disclosed |
| US-4246894-A | Method and system for administering a dissociative, unconscious type of anesthesia | HAMACHER EDWARD N | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013689-A1 | Method for treating pain | OPRL1, OPRK1, ACHE | DRD3 363/4885OPRM1 14/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.